Literature DB >> 12901798

A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function.

Yoshiyuki Endo, Hong Xin, Mitsu Takahashi, Toshihiro Nukiwa, Koichi Hagiwara.   

Abstract

p73, a close homolog of p53 tumor suppressor, induces growth arrest and apoptosis. However, its role in cancers is controversial because of the rarity of p73 mutations, lack of tumors in p73-knockout mice, and the presence of multiple isotypes, among which Delta N isotypes inhibit the function of TA isotypes. We analyzed three naturally occurring p73 mutants found in lung cancer cell lines, NCI-H1155, DMS 92 and A427. NCI-H1155 is a cell line that has a p73 mutation [p73(G264W)] in the DNA-binding domain, as well as a p53 mutation [p53(R273H)], which is frequently found in human cancers and has a "gain-of-function" characteristic. p73 alpha(G264W) not only lacks transactivation activity itself, but also suppressed the transactivation activity of the wild-type p73 alpha in a dose-dependent manner, indicating that p73 alpha(G264W) is a dominant-negative mutant. p73 alpha(G264W) failed to suppress colony formation. We tested two other mutations, p73(Del418) in DMS 92 and p73(Del603) in A427. Both mutants retained similar levels of transactivation activity and suppression of colony formation to those of wild-type p73. The biological significance of these two mutations is unclear. In NCI-H1155 cells the coexistence of mutations that abrogate the normal functions of p73 and p53 may indicate that each mutation confers an additive growth advantage upon the cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901798     DOI: 10.1111/j.1349-7006.2003.tb01508.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  3 in total

1.  Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy.

Authors:  Vibhor Gupta; Ponnusamy Kalaiarasan; Mohammad Faheem; Nishant Singh; Mohammad Askandar Iqbal; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.

Authors:  Michael W Harr; Timothy G Graves; Erin L Crawford; Kristy A Warner; Cheryl A M Reed; James C Willey
Journal:  Mol Cancer       Date:  2005-07-13       Impact factor: 27.401

3.  Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer.

Authors:  Elena Díaz-Rodríguez; Eduardo Sanz; Atanasio Pandiella
Journal:  Int J Oncol       Date:  2018-04-16       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.